1. Murray CJL, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science 1996; 274: 740–3.
2. Smith SC, Allen J, Blair SN et al. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease. 2006 update. Circulation 2006; 113: 2363–72.
3. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Media Medica, 2004.
4. Miettinen TA, Pushka P, Gylling H et al. Reduction of serum cholesterol with sitostanol-ester margarin in a mildly hypercholesterolemic population. N Engl J Med 1995; 333: 1308–12.
5. Gotto AM. Contemporary Diagnosis and Management of Lipid Disorders Handbooks in Helth Care Co., Newtoun, Pennsylvania, 2004; 115–21.
6. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AF CAPS/TexCAPS. JAMA 1998; 279: 1615–22.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S). Lancet 1994; 344: 1383–9.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
9. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipid on clinical events in the West of Scotland Coronary Prevention Study (WOSCOP). Circulation 1998; 97: 1440–5.
10. The Longterm Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 1998; 339: 1349–57.
11. Сарано Н.Е., Козлов С.Г., Творогова М.Г. Комбинированная терапия флувастатином и фенофибратом больных ишемической болезнью сердца и сахарным диабетом 2-го типа со смешанной гиперлипидемией. Кардиология. 2003; 4: 30–5.
12. Ballantyne CM, Herd JA, Ferlic LL et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99: 736–43.
13. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
14. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685–96.
15. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291, 9: 1071–80.
16. Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or atorvastatin evaluation and infection therapy thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
17. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35.
18.Pedersen TR, Faergeman O, Kastelein JJ et al. High dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–45.
19. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial), Am J Cardiol 2003; 92: 152–60.
20. Rubins HB, Robins SJ, Collins D et al. Veterans Affairs High Density Lypoprotein Cholesterol Intervention Trial Study Group. Gemfibrosil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–8.
21. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Lancet 2005; 366: 1849–61.
22. Canner PL, Berge KG,Wenger NK et al. Fifteen years mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55.
23. Aronov DM, Keenan JM, Akhmedzhanov NM et al. Clinical trial of waxmatrix sustained-release niacin in a Russia population with hypercholesterolemia. Arch Farm Med 1996; 5: 567–75.
24. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447–55.
25. Schrott HG, Bittner V, Vittinghoff E et al. Adherence to the National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study(HERS). JAMA 1997; 277: 1281–6.
26. ILIB international lipid information bureau. Dislipidemia and Coronary Heart Disease. 3rd ed. N.Y., 2003.
27. Grandy SM, Cleeman JI, Merz CN et al. Coordinating Committee of the National Cholesterol Education Program. Implication of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720–32.
28. Susekov A, Kulev B, Zubareva M et al. Effect of simvastatin 20 and 80 mg/day on function and structure in CHD patients with familial hypercholesterolemia. Final results of the ESCAPE study. Circulation 2006; 114 (18) Suppl. II: II–318.
29. Tardif JC, Cote G, Lesperance J. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997; 337 (6): 365–72.
30. Kita T, Nagano Y, Yokode M et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Nat Acad Sci USA 1987; 84: 5928–31.
31. Каминный А.И., Ланкин В.З., Каминная В.И. и др. Положительное влияние антиоксиданта пробукола на частоту и степень рестенозирования коронарных артерий после транслюминальной баллонной коронарной ангиопластики. Кардиоваск. тер. и профил. 2006; 5: 32–5.
32. Giveria F. (International Panel on Management of familial hypercholesterolemia) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173: 55–68.
33. Kukharchuk V, Konovalov G, Vedernikov A., Long-term application of three types of sorbents for LDL-apheresis. Plasma Ther Transfus. Technol 1988; 9: 45–7.
34. Кухарчук В.В., Коновалов Г.А., Покровский С.Н. Иммуносорбция липопротеидов низкой плотности (ЛНП-аферез) в лечении больных с нарушениями липидного обмена. Методические рекомендации для врачей. М., 2000.

В.В.Кухарчук

ФГУ Российский кардиологический научно-производственный комплекс Росмедтехнологий, Москва